Author:
Jokelainen Otto,Rintala Teemu J.,Fortino Vittorio,Pasonen-Seppänen Sanna,Sironen Reijo,Nykopp Timo K.
Abstract
AbstractHyaluronan (HA) accumulation in clear cell renal cell carcinoma (ccRCC) is associated with poor prognosis; however, its biology and role in tumorigenesis are unknown. RNA sequencing of 48 HA-positive and 48 HA-negative formalin-fixed paraffin-embedded (FFPE) samples was performed to identify differentially expressed genes (DEG). The DEGs were subjected to pathway and gene enrichment analyses. The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma (TCGA-KIRC) data and DEGs were used for the cluster analysis. In total, 129 DEGs were identified. HA-positive tumors exhibited enhanced expression of genes related to extracellular matrix (ECM) organization and ECM receptor interaction pathways. Gene set enrichment analysis showed that epithelial–mesenchymal transition-associated genes were highly enriched in the HA-positive phenotype. A protein–protein interaction network was constructed, and 17 hub genes were discovered. Heatmap analysis of TCGA-KIRC data identified two prognostic clusters corresponding to HA-positive and HA-negative phenotypes. These clusters were used to verify the expression levels and conduct survival analysis of the hub genes, 11 of which were linked to poor prognosis. These findings enhance our understanding of hyaluronan in ccRCC.
Publisher
Springer Science and Business Media LLC
Reference137 articles.
1. Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209–249 (2021).
2. Bukavina, L. et al. Epidemiology of renal cell carcinoma: 2022 update. Eur. Urol. 82, 529–542 (2022).
3. Hsieh, J. J. et al. Renal cell carcinoma. Nat. Rev. Dis. Primers 3, 66 (2017).
4. Alaghehbandan, R., Siadat, F. & Trpkov, K. What’s new in the WHO 2022 classification of kidney tumours?. Pathologica 115, 8–22 (2023).
5. Goodstein, T., Yang, Y., Runcie, K., Srinivasan, R. & Singer, E. A. Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma. Curr. Opin. Oncol. 35, 206–217 (2023).